Objective: To reassess iron supplementation practice safety in very low birth weight (VLBW) preterm infants receiving restrictive red blood cell transfusions during initial hospitalization.
Introduction
Relative to full-term infants, preterm infants are at risk of early onset of iron deficiency 1 because of low iron stores in proportion to birth weight, phlebotomy/blood testing, 2 prolonged periods of illness without iron supplementation and rapid 'catch-up' growth. Neurodevelopment deficits related to iron deficiency with or without anemia may not be reversible by iron supplementation 3 and can predispose the infant to long-term cognitive and motor impairment 4, 5 and to impaired mental and psychomotor function. 6 Therefore, supplementation of early iron fortified formula or iron preparation was advocated. [7] [8] [9] [10] In contrast, preterm infants, especially very low birth weight (VLBW) and extremely low birth weight, who receive multiple red blood cell transfusions (RBCTs), may be predisposed to iron overload 11, 12 that is involved in oxygen free radical formation and oxidative stress and in the pathogenesis of chronic illnesses. 13, 14 In addition to direct oxidative properties, large iron doses may reduce the absorption of vitamin E that is know for its antioxidant activity, and hence exacerbate anemia. 12 It is noteworthy that an animal model showing that increased murine neonatal iron intake resulted in Parkinson-like neurodegeneration with age. 15 Given that accurate iron status requires multiple biomarkers of iron storage and transport adequacy and in the absence of standardized tests in the neonatal period, iron deficiency or iron overload is estimated by indirect measures such as hemoglobin(Hb), ferritin and soluble transferrin receptor (sTfR). Few protocols suggested limiting RBCTs by applying restrictive transfusion guidelines, 16, 17 and thus minimizing the volumes of transfused blood to VLBW infants. However, there are insufficient data to determine whether infants, who receive restrictive RBCTs, are in further need of iron supplementation or might be exposed to iron overload. We aimed to reassess the safety of our iron supplementation practice for VLBW preterm infants receiving restrictive RBCTs. A normative reference value of ferritin, using similar method of analysis, was adopted from previously set standards of cord-blood ferritin concentration 18 to indicate adequate iron status of our preterm infants during initial hospitalization.
Methods

Study design and subjects
In this prospective, observational, cohort study, all VLBW preterm infants (birth weight p1500 g, <37 weeks gestation), who were admitted to our Neonatal Intensive Care Unit between January 2004 and June 2008, were screened for study eligibility. Infants were included only if their iron status was documented during four study periods (0 (p24 h) and 2, 4 and 8 weeks) and if they were followed-up for at least 3 months to determine the presence of morbidity associated with prematurity. Infants who did not meet the criteria for inclusion or died during the study period were defined as dropouts and were excluded from the final analysis. Other exclusion criteria were major anomalies, acute or chronic fetal blood loss, hemolytic disease, any intrauterine transfusion (that is, twin-to-twin transfusion syndrome, fetomaternal or maternofetal transfusion), baby considered not viable and no parental consent (Figure 1 ). The study protocol was approved by the Institutional Review Board of Meir Medical Center and written informed parental consent was obtained. Our protocol for restrictive RBCTs levels was based on collective experience and consensus building among our neonatologists. RBCT (15 to 20 cc kg -1 ) was given only when hematocrit level fell below the assigned value. The transfusion threshold levels were lower with age and improvement in infants' condition, reflecting the widely held view that older and more stable infants could safely tolerate lower hematocrit levels. During the first 14 days of life, while in need for assisted ventilation, infants received RBCTs if their hematocrit levels fell below 35% of the assigned value. Although receiving nasal continuous positive airway pressure or supplemental oxygen, their hematocrit levels were kept above 28%. If on room air, they were kept at hematocrit above 23%. After 14 days of life, RBCTs were given if hematocrit level was below 30% for the infants in need for assisted ventilation, below 25% for the infants receiving nasal continuous positive Iron for preterm infants receiving RBCTs S Arnon et al airway pressure or supplemental oxygen, and below 20% for those on room air.
Procedure and protocol
Study analysis
A list of the laboratory measurements analyzed during the 4 study period is provided in Table 1 . Blood samples were centrifuged within 2 h and stored in aliquots at À80 1C. Serum ferritin was measured by chemiluminescent immunoassay (Chiron Diagnostics, Walpole, MA, USA) and detection limit was 2.5 mg l -1 . Alfa-tocopherol levels were measured by high-pressure liquid chromatography and serum iron by colorimetric assay (TinaQuant Assay, Roche Diagnostics, Basel, Switzerland) with detection limits of 0.5 mg per 100 ml. Complete blood counts were performed on a cell counter (Advia 120, Fisher Diagnostics, Middletown, VA, USA). The sTfR was measured by rate nephelometry (Tina-Quant Assay; Roche Diagnostics) and detection limit was 0.068 mg l -1 .
The complete blood counts were performed on a cell counter (Abbott CD3500, Abbott, Wiesbaden, Germany).
Evaluation was delayed if C-reactive protein were taken for clinical reasons and were higher than 2 mg per 100 ml 48 h before and 48 h after blood sampling and if the infant were treated for infection. The laboratory personnel were blinded to the medical history of the infants. Reticulocytes were counted manually by two technicians and the mean value was recorded.
As part of routine care, at 1 month of age, all infants were examined by a Pediatric Ophthalmologist for the presence of retinopathy of prematurity. If indicated, they were further referred for outpatient follow-up and examinations were repeated until complete vascularization of the retina or until retinopathy was stable for at least 3 months. Screening head ultrasound to detect intraventricular hemorrhage was carried out routinely by the same examiner at the first week of life, at 1 month, and before discharge. The incidence of necrotizing enterocolitis stage XIIA, cultureproven sepsis, periventricular leukomalacia and bronchopulmonary dysplasia (requiring supplemental oxygen at >36 weeks gestation) were recorded during the study period.
Normative reference for cord-blood serum ferritin levels The ferritin levels of our transfused and non-transfused infants were compared with a gestation-matched normative reference for cord-blood ferritin levels. 18 Similar methods for measuring serum ferritin were used.
Statistical analysis
Statistical analysis was performed using the Statistica 8 software (StatSoft, Tulsa, OK, USA). Means, s.d., median, minimum and maximum were calculated for quantitative data. Normally distributed data were expressed as mean and s.d. and non-normally as median and range. Continuous data were analyzed using the Student's t-test or Mann-Whitney rank test for non-parametric data. Dichotomous outcome measures were analyzed using the Table 1 Laboratory measurements of both transfused and non-transfused groups during the four study period 
Results
In all, 236 infants of the transfused group and 166 of the non-transfused group met the inclusion criteria for this study (Figure 1) . No significant differences were noted between the infants included in the final analysis and dropouts regarding gender, gestational age, birth weight, appropriateness for gestational age (>percentile 3) and weight at 8 weeks of age.
Except for phlebotomy losses, which were significantly more common in the transfused group than in the non-transfused group (35 (12 to 49) vs 18 (8 to 26) ml kg -1 , respectively, P ¼ 0.042), no other significant differences were found for gender, gestational age, birth weight, appropriateness for gestational age, weight at 8 weeks of age, daily oral iron intake and day of full feed initiation (>100 cc kg -1 per day) (all P>0.081). Compared with nil in the non-transfused group, the total volume of blood transfused, following restrictive RBCT guidelines without erythropoietin administration, was 35 (12 to 65) ml in the transfused group. RBCT was given at 5 (1 to 41) days.
At p24 h, the iron status of the transfused group and nontransfused group was similar. Compared with the non-transfused infants, the infants of the transfused group had significantly higher Hb, iron and ferritin levels at 2, 4 and 8 weeks and lower sTfR at 4 and 8 weeks (P<0.05, Table 1 ). No significant differences were found for reticulocyte count and vitamin E levels between both groups. At 8 weeks of age, the cord-blood serum ferritin levels (115 mg l -1 , corresponding to the 50th percentile) of a normative reference group 18 were higher than those of our transfused and non-transfused groups (79 (43 to 107), and 48 (22 to 89) mg l -1 , respectively).
The infants of both study groups had similar incidences of retinopathy of prematurity, necrotizing enterocolitis XIIA, intraventricular hemorrhage, periventricular leukomalacia and bronchopulmonary dysplasia (all P>0.255). The difference between episodes of sepsis also did not reach statistical significance (26/166 vs 51/236, P ¼ 0.189). No association was found between ferritin, iron and Hb levels of both groups and incidence of morbidities of prematurity (all P>0.252).
Discussion
Considering that there are no standard recommendations on therapeutic iron dose, timing of iron supplement and target values of iron status indices to build effective treatment polices, local protocols are commonly used. As RBCT volumes and timing vary greatly between individuals, we reasoned that it would still be room for additional iron supplementation in the era of adhering to restrictive transfusion guidelines. 16, 17 We showed that treating preterm infants with iron supplementation starting at 4 weeks of age, regardless whether they received or not RBCTs under restrictive guidelines, resulted in higher iron status of the transfused infants at 8 weeks. Yet, adopting the equation of cord-blood levels as a reference value for iron stores no signs of iron excess were, in fact, documented when these serum ferritin levels were compared with those of cord-blood ferritin levels of a gestation-matched normative reference group. 18 Furthermore, although our two study groups vary in terms of acuity of illness and phlebotomy losses leading to RBCTs, resulting most probably from a higher need for disease surveillance in the transfused group, no increased incidence of prematurity associated diseases was found in this group. It is noteworthy that other cordblood iron indicators such as sTfR were not compared because of the different methods used for measurement. 19 Iron load because of multiple transfusions 11, 12 mainly results from accelerated breakdown of red blood cells. 20 Plasma nontransferrin bound iron that significantly increases in preterm infants after RBCT partly exists in the ferrous pro-oxidant form; 21 therefore, the association between high transfusion requirements early in life and greater risk of diseases related to oxygen free radicals formation such as retinopathy of prematurity and bronchopulmonary dysplasia were suggested. 12, 13 However, randomized clinical trials established no causal link between transfusion practice and morbidities associated with prematurity. 22 Furthermore, no direct relationship was shown between oxidative injury and increased risk of chronic lung disease.
14 Others showed that despite increased non-transferrin-bound iron levels, erythrocyte transfusion neither increased oxidative stress nor impaired antioxidant status. 21 We also found that iron supplementation at 4 weeks of age in preterm infants receiving RBCTs did not increase hemolysis, decrease vitamin E levels or increase the incidence of prematurity-associated diseases.
The potentially hazardous effect of RBCTs varies greatly with the volume transfused. Post-mortem liver analysis of VLBW infants, who received more than 180 ml of transfused blood, showed high hepatic iron concentrations and/or histochemical changes compatible with iron toxicity. The investigators concluded that routine iron supplementation would probably be unnecessary in preterm infants receiving above the aforementioned volume. 11 We used a judicious and restrictive RBCT policy to minimize blood loss with much <180 ml of transfused blood. To answer the question what level of iron is safe, Braekke et al. 23 treated stable preterm infants with relatively high-dose oral iron (18 mg) and evaluated antioxidant status and oxidative stress 1 week after starting therapy. Although this dose of iron, which was not adjusted for weight, was several times higher than that recommended by the American Academy of Pediatrics (2 to 4 mg kg -1 per day of elemental iron for premature infants), 24 using sensitive and specific indicators of hydroxyl radicals, no evidence of oxidative stress was found. Similarly, Miller et al. 25 examined iron therapy in the absence of erythropoietin treatment and showed stable blood and urine isoprostanes and no oxidative injuries in premature infants, who were given a sliding-scale ferrous sulfate dose of as high as 12 mg kg -1 per day. In contrast, others found much higher ferritin levels than ours at 8 weeks of age (220 mg l -1 vs 79 mg l -1 , respectively) after RBCTs in the ferrous pro-oxidant form that were associated with retinopathy of prematurity and/or bronchopulmonary dysplasia. However, no range of transfused volumes was reported. 21 We recognize several limitations of our study. No individualization of iron supplementation according to iron status indices was offered; nevertheless, iron that is advocated for all preterm infants prone to iron deficiency regardless of iron status was used herein as a preventive treatment for VLBW infants. We were also not able, because of lack of raw data, to show that our ferritin concentrations at 8 weeks of age were significantly lower than those reported in cord blood; 18 nevertheless, a 32%-difference between the median values still exists between the findings. No data are available on the post-neonatal neurodevelopmental outcomes of transfused infants receiving iron supplement. These data might have helped deciding on the optimal iron dose, yet the topic is beyond the scope of our study and further data are needed to evaluate the benefits and effects of this practice.
Conclusion
Preterm infants who received RBCTs concomitant with 5 mg kg -1 per day of iron supplementation, starting at 4 weeks of age, had higher iron stores and Hb concentrations than infants who did not receive RBCTs during the first 8 weeks of life. At 8 weeks, ferritin levels, as a measure of iron status, did not exceed that of a normative reference cord-blood value. 18 This combined practice was also not associated with additional adverse effects or increased incidence of neonatal morbidity. Given these findings, our policy of iron supplementation for preterm infants, who were managed by a restrictive RBCT policy to minimize blood loss during the first 8 weeks of life, seems a judicious and safe practice, in terms of iron status, to be followed until practice guidelines are established.
